No Data
No Data
Mei Hao Medical (301363.SZ): Malaysia's self-owned production bases Phase 1 and Phase 2 have been put into operation.
On November 27, Gelonghui reported that Meihao Medical (301363.SZ) stated on the investor interaction platform that the main foreign sales countries are currently Singapore, Australia, and others. The company has its own production base in Malaysia, with the first and second phases already in production, and the third phase under construction, meeting the needs of different clients in various supply chain markets.
Returns On Capital Signal Tricky Times Ahead For MeHow Innovative (SZSE:301363)
Meihao Medical (301363.SZ): The cumulative repurchase of 0.4842% of the shares.
格隆汇 November 4th | Meihao Medical (301363.SZ) announced that as of October 31, 2024, the company has repurchased a total of 1,968,851 shares of the company through a designated securities account using centralized auction trading method, accounting for 0.4842% of the total share capital. The highest fill price was 28.31 yuan/share, the lowest fill price was 22.80 yuan/share, and the total fill amount was 50,093,656.31 yuan (excluding transaction costs).
Beautiful Healthcare: 2024 Third Quarter Report
Meihao Medical (301363.SZ): The net income for the first three quarters was 0.258 billion yuan, a 14.07% year-on-year decrease.
Gelonghui October 24th 丨 Meihao Medical (301363.SZ) released its third quarter report. The company achieved revenue of 1.157 billion yuan in the first three quarters, a year-on-year increase of 10.86%; net income attributable to shareholders of the listed company was 0.258 billion yuan, a year-on-year decrease of 14.07%; net income after deducting non-recurring gains and losses was 0.248 billion yuan, a year-on-year decrease of 11.15%; basic earnings per share was 0.64 yuan/share.
Meihao Medical (301363.SZ) released its performance for the first three quarters, with net income of 0.258 billion yuan, a year-on-year decrease of 14.07%.
Meihao Medical (301363.SZ) released the third quarter report of 2024, with revenue in the first three quarters reaching 11...
No Data